Scholes Delia, Heidrich Fred E, Yarbro Patricia, Lindenbaum Jeff E, Marrazzo Jeanne M
Center for Health Studies, Group Health Cooperative, Seattle, WA 98101, USA.
Sex Transm Dis. 2007 Nov;34(11):837-9. doi: 10.1097/OLQ.0b013e31805ba860.
To evaluate the feasibility and efficacy of population-based outreach strategies to improve genital Chlamydia trachomatis (CT) screening in men.
In a randomized trial, male enrollees ages 21-25 (n = 8820) were selected from the automated files of Group Health Cooperative and randomized to: a letter + test-request card for a CT urine home sampling kit (arm 1, n = 2940); a letter + mail-back sampling kit (arm 2, n = 2940); or a usual care control (arm 3, n = 2940). One reminder was sent to arms 1 and 2. The outcome was CT testing rates in the 4 months postrandomization.
105 of 2940 (3.6%) men in arm 1 and 230 of 2940 (7.8%) in arm 2 returned mailed specimens. All 335 respondents were sexually experienced, 43% had >2 sex partners in the past year, and 80% reported no genitourinary symptoms. Compared to arm 3, the relative risk of being tested was 5.6 (95% confidence interval (CI) 3.6-8.7) for arm 1 and 11.1 (95% CI 7.3-16.9) for arm 2. Arm 2 was significantly more likely to be tested than arm 1. CT prevalence for mailed-back specimens was 1.0% (1 of 105) for arm 1 and 2.6% (6 of 230) for arm 2; 70% of all positive intervention tests were from mailed samples.
Both strategies resulted in significantly higher CT testing than usual care, but the intervention response rate was low (5.7% overall). Direct kit mailing performed best. In US populations, the value of mailed outreach strategies to men must be considered in the context of other CT screening priorities.
评估基于人群的外展策略在改善男性沙眼衣原体(CT)筛查方面的可行性和有效性。
在一项随机试验中,从健康合作组织的自动档案中选取年龄在21至25岁之间的男性参与者(n = 8820),并随机分为:一张CT尿液家庭采样试剂盒的信件 + 测试请求卡(第1组,n = 2940);一封信件 + 回邮采样试剂盒(第2组,n = 2940);或常规护理对照组(第3组,n = 2940)。向第1组和第2组发送了一次提醒。结果是随机分组后4个月内的CT检测率。
第1组2940名男性中有105名(3.6%),第2组2940名男性中有230名(7.8%)返回了邮寄的样本。所有335名受访者都有性经历,43%的人在过去一年中有超过2个性伴侣,80%的人报告没有泌尿生殖系统症状。与第3组相比,第1组接受检测的相对风险为5.6(95%置信区间(CI)3.6 - 8.7),第2组为11.1(95%CI 7.3 - 16.9)。第2组接受检测的可能性明显高于第1组。第1组回邮样本的CT患病率为1.0%(105例中的1例),第2组为2.6%(230例中的6例);所有阳性干预检测的70%来自邮寄样本。
两种策略都使CT检测率显著高于常规护理,但干预反应率较低(总体为5.7%)。直接邮寄试剂盒效果最佳。在美国人群中,必须在其他CT筛查重点的背景下考虑向男性邮寄外展策略的价值。